Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy

Clinical Chemistry

Volumn 49, Issue 6, 2003, Pages 880-886

  Venge, Per ^a,b   Johnston, Nina ^a   Lagerqvist, Bo ^a   Wallentin, Lars ^a   Lindahl, Bertil ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; EDETIC ACID; PLACEBO; TROPONIN I;

ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ARTICLE; ASSAY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HEART INJURY; HEART MUSCLE INJURY; HUMAN; INTERMETHOD COMPARISON; LIAISON CARDIAC TROPONIN I ASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PROGNOSIS; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANGINA, UNSTABLE; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TROPONIN I;

EID: 0038697633     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.6.880     Document Type: Article

References (20)

1. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.
2. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
3. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996;93:1651-7.
4. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
5. Luscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. Circulation 1997;96:2578-85.
6. Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum. Am Heart J 2000;139:461-75.
7. Hamm Cw, Braunwald E. A classification of unstable angina revisited. Circulation 2000;102:118-22.
8. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979-86.
9. Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002;89:1035-41.
10. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999;354:701-7.
11. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during InStability in Coronary artery disease. Lancet 2000;356: 9-16.
12. Venge P, Lindahl B, Wallentin L. New generation cardiac troponin I assay for the Access immunoassay system. Clin Chem 2001; 47:959-61.
13. Yeo KT, Quinn-Hall KS, Bateman SW, Fischer GA, Wieczorek S, Wu A. Functional sensitivity of cardiac troponin assays and its implications for risk stratification for patients with acute coronary syndromes. In: Adams JEI, Apple FS, Wu A, eds. Markers in cardiology: current and future clinical applications. New York: Futura Publishing, 2001:23-9.
14. Uettwiller-Geiger D, Wu AH, Apple FS, Jevans AW, Venge P, Olson MD, et al. Multicenter evaluation of an automated assay for troponin I. Clin Chem 2002;48:869-76.
15. Zaninotto M, Mion M, Altinier S, Forni M, Cacciavillani L, Plebani M. Quality specifications and Liaison troponin I analytical and clinical characteristics [Abstract]. Clin Chem 2002;48(Suppl 6): A84.
16. Panteghini MR, Pagani F, Stefini F. Analytical performance of the BYK-Sangtec's Liaison Troponin I assay evaluated according to the IFCC recommendations [Abstract]. Clin Chem 2002;48(Suppl 6):A85.
17. Giuliani I, Bertinchant JP, Lopez M, Coquelin H, Granier C, Laprade M, et al. Determination of cardiac troponin I forms in the blood of patients with unstable angina pectoris. Clin Biochem 2002;35: 111-7.
18. Mockel M, Heller G Jr, Berg K, Klefisch F, Danne O, Muller C, et al. The acute coronary syndrome diagnosis and prognostic evaluation by troponin I is influenced by the test system affinity to different troponin complexes. Clin Chim Acta 2000;293:139-55.
19. Wu AH, Feng YJ, Moore R, Apple FS, McPherson PH, Buechler KF, et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. Clin Chem 1998;44: 1198-208.
20. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000;102:1221-6.